GV Research Platform (GVRP) has partnered with Yurogen Biosystems to aim expanding access for Indian biotechnology and pharmaceutical companies, as well as academic research institutions, to advanced antibody discovery capabilities supporting early-stage drug discovery and translational research.

Under this partnership, GVRP will serve as the commercial interface for Yurogen Biosystems in India, enabling streamlined market access, client engagement and programme coordination, while all scientific execution and service delivery will continue to be carried out by Yurogen Biosystems.

The collaboration responds to the growing demand within India’s life sciences ecosystem for globally benchmarked antibody discovery services, particularly in areas requiring deep biological insight at early stages of research. By combining Yurogen’s scientific expertise with GVRP’s understanding of the Indian research ecosystem, the partnership enables smoother and more efficient engagement for domestic innovators.

Commenting on the partnership, Kalyan Korisapati, Co-Founder and CEO, GV Research Platform, said, “This partnership with Yurogen Biosystems reflects our focus on expanding meaningful access to advanced monoclonal antibody discovery platforms such as SMab. By enabling faster and more precise early discovery, we aim to support Indian innovators in advancing targeted therapies efficiently. As the local commercial interface, GVRP will simplify engagement and facilitate access to globally benchmarked discovery capabilities.”

Through this partnership, GVRP and Yurogen Biosystems aim to strengthen global scientific collaboration and support the continued growth of India’s drug discovery ecosystem by improving access to specialised early discovery capabilities.

Dr Yang Lou, CEO, Yurogen Biosystems, added, “India is emerging as an important centre for early-stage biomedical research. Partnering with GVRP allows us to engage more closely with the Indian biopharma community through a trusted local presence, while continuing to deliver our services with the same scientific rigour and quality standards.”